These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 26625317

  • 1. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
    Airiau K, Prouzet-Mauléon V, Rousseau B, Pigneux A, Jeanneteau M, Giraudon M, Allou K, Dubus P, Belloc F, Mahon FX.
    Oncotarget; 2016 Jan 05; 7(1):845-59. PubMed ID: 26625317
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
    Inaba K, Oda K, Ikeda Y, Sone K, Miyasaka A, Kashiyama T, Fukuda T, Uehara Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T.
    Gynecol Oncol; 2015 Aug 05; 138(2):323-31. PubMed ID: 26033306
    [Abstract] [Full Text] [Related]

  • 3. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.
    Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C, Rigas D, Vajda K, Ferris LA, Lanuti M, Wright CD, Raskin KA, Cahill DP, Shin JH, Keyes C, Sequist LV, Piotrowska Z, Farago AF, Azzoli CG, Gainor JF, Sarosiek KA, Brown SP, Coxon A, Benes CH, Hughes PE, Hata AN.
    Cancer Discov; 2018 Dec 05; 8(12):1598-1613. PubMed ID: 30254092
    [Abstract] [Full Text] [Related]

  • 4. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B, Cuyàs E, Bosch-Barrera J, Massaguer A, de Llorens R, Martin-Castillo B, Brunet J, Salazar R, Menendez JA.
    Oncotarget; 2016 Dec 13; 7(50):82185-82199. PubMed ID: 27636997
    [Abstract] [Full Text] [Related]

  • 5. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
    Li J, Chen Y, Wan J, Liu X, Yu C, Li W.
    Br J Pharmacol; 2014 Jul 13; 171(13):3182-95. PubMed ID: 24571452
    [Abstract] [Full Text] [Related]

  • 6. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
    Huang S, Li C, Zhang X, Pan J, Li F, Lv Y, Huang J, Ling Q, Ye W, Mao S, Huang X, Jin J.
    Mol Oncol; 2020 Oct 13; 14(10):2560-2573. PubMed ID: 32519423
    [Abstract] [Full Text] [Related]

  • 7. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.
    Int J Cancer; 2013 Nov 13; 133(9):2089-101. PubMed ID: 23629727
    [Abstract] [Full Text] [Related]

  • 8. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
    Vena F, Li Causi E, Rodriguez-Justo M, Goodstal S, Hagemann T, Hartley JA, Hochhauser D.
    Clin Cancer Res; 2015 Dec 15; 21(24):5563-77. PubMed ID: 26228206
    [Abstract] [Full Text] [Related]

  • 9. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
    Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, Boyd KL, Strickland SA, Sensintaffar J, Hogdal LJ, Ayers GD, Olejniczak ET, Fesik SW, Savona MR.
    Cancer Discov; 2018 Dec 15; 8(12):1566-1581. PubMed ID: 30185627
    [Abstract] [Full Text] [Related]

  • 10. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.
    Sale MJ, Cook SJ.
    Biochem J; 2013 Mar 01; 450(2):285-94. PubMed ID: 23234544
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
    Zhao J, Niu X, Li X, Edwards H, Wang G, Wang Y, Taub JW, Lin H, Ge Y.
    Oncotarget; 2016 Jun 07; 7(23):34785-99. PubMed ID: 27166183
    [Abstract] [Full Text] [Related]

  • 12. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
    Hu S, Niu H, Inaba H, Orwick S, Rose C, Panetta JC, Yang S, Pounds S, Fan Y, Calabrese C, Rehg JE, Campana D, Rubnitz JE, Baker SD.
    J Natl Cancer Inst; 2011 Jun 08; 103(11):893-905. PubMed ID: 21487100
    [Abstract] [Full Text] [Related]

  • 13. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
    Crassini K, Stevenson WS, Mulligan SP, Best OG.
    Leuk Lymphoma; 2015 Jun 08; 56(12):3407-17. PubMed ID: 25804768
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S.
    Blood; 2012 Jun 21; 119(25):6089-98. PubMed ID: 22446485
    [Abstract] [Full Text] [Related]

  • 15. ABT-263 induces G1/G0-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro.
    Lin QH, Que FC, Gu CP, Zhong DS, Zhou D, Kong Y, Yu L, Liu SW.
    Acta Pharmacol Sin; 2017 Dec 21; 38(12):1632-1641. PubMed ID: 28713162
    [Abstract] [Full Text] [Related]

  • 16. The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia.
    Espinoza JL, Elbadry MI, Taniwaki M, Harada K, Trung LQ, Nakagawa N, Takami A, Ishiyama K, Yamauchi T, Takenaka K, Nakao S.
    Cancer Lett; 2017 Aug 01; 400():127-136. PubMed ID: 28456658
    [Abstract] [Full Text] [Related]

  • 17. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment.
    Crassini K, Shen Y, Stevenson WS, Christopherson R, Ward C, Mulligan SP, Best OG.
    Br J Haematol; 2018 Aug 01; 182(3):360-372. PubMed ID: 29767411
    [Abstract] [Full Text] [Related]

  • 18. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
    Kiprianova I, Remy J, Milosch N, Mohrenz IV, Seifert V, Aigner A, Kögel D.
    Neoplasia; 2015 Jul 01; 17(7):564-73. PubMed ID: 26297434
    [Abstract] [Full Text] [Related]

  • 19. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C, Friess T, Birzele F, Kiialainen A, Dangl M.
    J Hematol Oncol; 2016 Jun 28; 9(1):50. PubMed ID: 27353420
    [Abstract] [Full Text] [Related]

  • 20. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
    Kiga M, Tanzawa F, Iwasaki S, Inaba F, Fujiwara K, Iwadare H, Echigo T, Nakamura Y, Shibata T, Suzuki K, Yasumatsu I, Nakayama A, Sasazawa Y, Tashiro E, Imoto M, Kurakata S.
    Anticancer Drugs; 2012 Jan 28; 23(1):119-30. PubMed ID: 22008853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.